Roche’s Genentech unit reported first-look Phase 3 results for divarasib in previously treated KRAS G12C non-small-cell lung cancer, using the head-to-head Krascendo 1 trial design. The company said divarasib demonstrated clinically meaningful and statistically significant improvements in overall survival and progression-free survival versus approved therapies from Amgen and Bristol Myers Squibb, with no new safety signals and side effects described as manageable and reversible. Genentech said it expects to submit the Phase 3 data to regulators and present details at an upcoming medical meeting. Roche is positioning divarasib as a potential new standard for second-line KRAS G12C NSCLC as it also evaluates earlier-line regimens in ongoing studies, including divarasib plus Keytruda combinations. Separately, the Roche-backed narrative is reinforced by a second cluster item in this dataset describing divarasib’s head-to-head Phase 3 success in narrative terms; together they indicate Roche is actively using comparative efficacy evidence to expand within the KRAS G12C competitive set.